Compare Cytokinetics Inc (CYTK) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Standard Lithium Ltd — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Standard Lithium Ltd trades at $2.31 (market cap $577.14M). The key difference: Cytokinetics Inc is far larger — about 19.3× Standard Lithium Ltd's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| CYTK | SLI | |
|---|---|---|
Market Cap | $11.12B | $577.14M |
Sector | Technology | Basic Materials |
52-Week High | $87.26 | $5.65 |
52-Week Low | $33.23 | $2.29 |
Enterprise Value | $11.59B | $436.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
SLI trades at $2.29, down 6.91% today, with a bearish technical trend but oversold RSI readings. The company reported a net loss of $48.40 million in 2025, though it secured a $225 million DOE grant and key construction contracts for its Arkansas lithium project. Analyst consensus is unanimously bullish with 3 buy ratings.
The investment case hinges on successful project execution and lithium market dynamics. Near-term risks include cash burn and execution delays, but long-term upside exists if production targets are met. Investors should weigh high operational losses against strong institutional backing and strategic partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
